419 related articles for article (PubMed ID: 15183042)
1. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
2. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
3. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model.
Kondo N; Suzuki Y; Wakayama F; Tamai Y; Ji K; Fukui K; Fukuda I
Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass.
Tabata S; Yamaguchi S; Nagamine H; Tomita S; Arai S; Takemura H; Watanabe G
Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
[TBL] [Abstract][Full Text] [Related]
9. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
10. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
Chiang TM; Zhu J
Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
[TBL] [Abstract][Full Text] [Related]
11. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.
Wachtfogel YT; Kettner C; Hack CE; Nuijens JH; Reilly TM; Knabb RM; Kucich U; Niewiarowski S; Edmunds LH; Colman RW
Thromb Haemost; 1998 Oct; 80(4):686-91. PubMed ID: 9798991
[TBL] [Abstract][Full Text] [Related]
12. Thrombogenesis in sickle cell disease.
Tomer A; Harker LA; Kasey S; Eckman JR
J Lab Clin Med; 2001 Jun; 137(6):398-407. PubMed ID: 11385360
[TBL] [Abstract][Full Text] [Related]
13. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
14. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
[TBL] [Abstract][Full Text] [Related]
15. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Goto S; Tamura N; Ishida H; Ruggeri ZM
J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
[TBL] [Abstract][Full Text] [Related]
16. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
[TBL] [Abstract][Full Text] [Related]
17. Platelet activation after stenting with heparin-coated versus noncoated stents.
Gurbel PA; Bliden KP
Am Heart J; 2003 Oct; 146(4):E10. PubMed ID: 14564333
[TBL] [Abstract][Full Text] [Related]
18. Evidence for selective degradation of platelet GP IIb/IIIa complex after prolonged in vitro ventricular assist.
Serna DL; King BO; Huh J; Jalal R; Tran L; Chen JC
J Investig Med; 1998 Aug; 46(6):279-83. PubMed ID: 9737089
[TBL] [Abstract][Full Text] [Related]
19. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
[TBL] [Abstract][Full Text] [Related]
20. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins.
Liu CZ; Hur BT; Huang TF
Thromb Haemost; 1996 Oct; 76(4):585-91. PubMed ID: 8903000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
